All posts from in,

Can Mallinckrodt (MNK) Keep The Earnings Streak Alive? - Analyst Blog

Mallinckrodt plc MNK is set to report third-quarter fiscal 2015 results on Aug 4, 2015.

Mallinckrodt’s track record has been impressive. The company beat estimates in the last four quarters with a positive average earnings surprise of 24.58%. Let’s see how things are shaping up for this announcement.

Factors Influencing This Quarter

Although Mallinckrodt’s Specialty Brands and Specialty Generics segments will continue to drive revenues, currency fluctuations may affect sales this quarter. Moreover, the company said on its second-quarter fiscal 2015 call that it expects Specialty Generics sales to be slower in the upcoming quarters due to competitive pressure.

However, Ofirmev and Acthar (added to its portfolio last year upon the acquisitions of Cadence Pharmaceuticals and Questcor Pharmaceuticals, respectively) sales may support the top line.

During this quarter, Mallinckrodt acquired Ikaria Inc. to strengthen its business in the hospital market. With the addition of Inomax to its portfolio, Mallinckrodt gained access to the market for neonatal...